Investigation of new treatment strategy for metastatic bone tumor, combination of zoledronate and oncolytic adenovirus.
| Project/Area Number |
15K19999
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Takeda Ken 岡山大学, 医学部, 客員研究員 (70614923)
|
|---|
| Research Collaborator |
YAMAKAWA Yasuaki 岡山大学, 大学院医歯(薬)学総合研究科, 助教 (90636953)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 転移性骨腫瘍 / 腫瘍融解アデノウイルス / ゾレドロン酸 / 併用療法 / ゾレドロネート / 骨転移 / 併用効果 |
|---|
| Outline of Final Research Achievements |
The number of patients who have cancer and bone metastasis is increasing. We investigated new treatment strategy for bone metastasis, which is combination of oncolytic adenovirus(OBP-301) and zoledronate(ZOL). OBP-301 and ZOL showed the antitumor effect against cancer cells respectively and combination therapy of OBP-301 and ZOL showed antitumor effect more than single treatment. Also in cancer metastasis murine model, combination treatment showed more antitumor effect than single treatment.
This combination treatment might be a new treatment strategy against bone metastasis.
|
Report
(3 results)
Research Products
(2 results)
